Alpha 2.0
Login Register
» Articles » PMID: 2939863

Prolonged Midazolam Elimination Half-life

Overview
Journal Br J Clin Pharmacol
Specialty Pharmacology
Date 1986 Apr 1
PMID 2939863
Citations 30
Authors
J W Dundee
P S Collier
R J Carlisle
K W Harper
Affiliations
Soon will be listed here.
Abstract

The pharmacokinetics of a fixed dose of midazolam (0.3 mg kg-1 i.v.) were studied in detail in 115 healthy patients or volunteers and nine were found with a prolonged elimination half-life. A further 102 patients had an abbreviated pharmacokinetic study, of whom five showed a similar abnormality. Defective hepatic metabolism of midazolam may be a factor in the aetiology of what appears to be a true phenomenon, occurring in 6% of over 200 fit subjects given a standard dose of the drug.

Citing Articles

Anesthetic management using remimazolam in a patient with atrial flutter: a case report.

Lee J, Kim H, Kim Y, Lee J, Park J, Shin Y Am J Transl Res. 2022; 14(8):5754-5759.

PMID: 36105055 PMC: 9452332.

Quantification of CYP3A and Drug Transporters Activity in Healthy Young, Healthy Elderly and Chronic Kidney Disease Elderly Patients by a Microdose Cocktail Approach.

Rattanacheeworn P, Kerr S, Kittanamongkolchai W, Townamchai N, Udomkarnjananun S, Praditpornsilpa K Front Pharmacol. 2021; 12:726669.

PMID: 34603040 PMC: 8486002. DOI: 10.3389/fphar.2021.726669.

Remimazolam anesthesia for cardiac surgery with cardiopulmonary bypass: a case report.

Saito K, Ohno S, Maeda M, Hirata N, Yamakage M JA Clin Rep. 2021; 7(1):21.

PMID: 33677710 PMC: 7937000. DOI: 10.1186/s40981-021-00424-0.

A Pediatric Covariate Function for CYP3A-Mediated Midazolam Clearance Can Scale Clearance of Selected CYP3A Substrates in Children.

Brussee J, Krekels E, Calvier E, Palic S, Rostami-Hodjegan A, Danhof M AAPS J. 2019; 21(5):81.

PMID: 31250333 PMC: 6597607. DOI: 10.1208/s12248-019-0351-9.

A Review of Food-Drug Interactions on Oral Drug Absorption.

Deng J, Zhu X, Chen Z, Fan C, Kwan H, Wong C Drugs. 2017; 77(17):1833-1855.

PMID: 29076109 DOI: 10.1007/s40265-017-0832-z.

References
1.
Wilkinson G, SHAND D . Commentary: a physiological approach to hepatic drug clearance. Clin Pharmacol Ther. 1975; 18(4):377-90. DOI: 10.1002/cpt1975184377. View
2.
Sloan T, Mahgoub A, Lancaster R, Idle J, Smith R . Polymorphism of carbon oxidation of drugs and clinical implications. Br Med J. 1978; 2(6138):655-7. PMC: 1607381. DOI: 10.1136/bmj.2.6138.655. View
3.
Evans D, Mahgoub A, Sloan T, Idle J, Smith R . A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet. 1980; 17(2):102-5. PMC: 1048511. DOI: 10.1136/jmg.17.2.102. View
4.
Dundee J, Samuel I, Toner W, Howard P . Midazolam: a water-soluble benzodiazepine. Studies in volunteers. Anaesthesia. 1980; 35(5):454-8. DOI: 10.1111/j.1365-2044.1980.tb03821.x. View
5.
Allonen H, Ziegler G, Klotz U . Midazolam kinetics. Clin Pharmacol Ther. 1981; 30(5):653-61. DOI: 10.1038/clpt.1981.217. View